- $33.66m
- -$4.36m
- $84.51m
- 25
- 49
- 19
- 22
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.49 | ||
| Price to Tang. Book | 14.93 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.4 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -176.4% | ||
| Return on Equity | -213.73% | ||
| Operating Margin | -172.45% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 36.63 | 45.6 | 68.79 | 75.74 | 84.51 | 71.22 | 109.83 | 25.75% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six market areas, including oncology, rare diseases and gene therapy. Its dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend. Its late stage product candidates include Cosibelimab (anti-PD-L1 antibody), DFD-29 (modified release oral minocycline for the treatment of rosacea), CUTX-101 (copper histidinate injection for Menkes disease), IV Tramadol, Olafertinib (also known as CK-101, EGFR inhibitor for EGFR mutation-positive NSCLC), CAEL-101 (monoclonal antibody for AL amyloidosis) and Triplex (cytomegalovirus (CMV) vaccine).
Directors
- Lindsay Rosenwald CHM (66)
- Michael Weiss VCH (55)
- Eric Rowinsky VCH (64)
- Robyn Hunter CFO (60)
- George Avgerinos SVP
- Jimmie Harvey IND (69)
- Malcolm Hoenlein IND (77)
- Dov Klein IND (68)
- J. Jay Lobell IND (58)
- Kevin Lorenz IND (56)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 28th, 2006
- Public Since
- November 17th, 2011
- No. of Shareholders
- 432
- No. of Employees
- 186
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 19,234,526
- Address
- 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS, 33154
- Web
- https://www.fortressbiotech.com/
- Phone
- +1 7816524500
- Contact
- Jaclyn Jaffe
- Auditors
- KPMG LLP
Upcoming Events for FBIO
Fortress Biotech Inc Annual Shareholders Meeting
Fortress Biotech Inc Annual Shareholders Meeting
Q2 2024 Fortress Biotech Inc Earnings Release
Similar to FBIO
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
What is the Fortress Biotech share price?
As of Today at 19:08 UTC, shares in Fortress Biotech are trading at $1.75. This share price information is delayed by 15 minutes.
How has the Fortress Biotech share price performed this year?
Shares in Fortress Biotech last closed at $1.75 and the price had moved by -83.68% over the past 365 days. In terms of relative price strength the Fortress Biotech share price has underperformed the S&P500 Index by -86.42% over the past year.
What are the analyst and broker recommendations for Fortress Biotech?
The overall consensus recommendation for Fortress Biotech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Fortress Biotech dividend yield?
Fortress Biotech does not currently pay a dividend.
Does Fortress Biotech pay a dividend?
Fortress Biotech does not currently pay a dividend.
When does Fortress Biotech next pay dividends?
Fortress Biotech does not currently pay a dividend.
How do I buy Fortress Biotech shares?
To buy shares in Fortress Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Fortress Biotech?
As of the previous close price of $1.75, shares in Fortress Biotech had a market capitalisation of $33.66m.
Where are Fortress Biotech shares listed?
Here are the trading details for Fortress Biotech:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: FBIO
What kind of share is Fortress Biotech?
Based on an overall assessment of its quality, value and momentum Fortress Biotech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Fortress Biotech share price forecast for 2024?
The analyst consensus target price for shares in Fortress Biotech is $30.67. That is 1652.57% above the last closing price of $1.75.
Analysts covering Fortress Biotech currently have a consensus Earnings Per Share (EPS) forecast of -$5.80 for the next financial year.
What is the trend in the Fortress Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fortress Biotech. Over the past six months, its share price has underperformed the S&P500 Index by -20.12%.
As of the last closing price of $1.75, shares in Fortress Biotech were trading -52.11% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Fortress Biotech PE Ratio?
The Fortress Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Fortress Biotech?
Fortress Biotech's management team is headed by:
- Lindsay Rosenwald - CHM
- Michael Weiss - VCH
- Eric Rowinsky - VCH
- Robyn Hunter - CFO
- George Avgerinos - SVP
- Jimmie Harvey - IND
- Malcolm Hoenlein - IND
- Dov Klein - IND
- J. Jay Lobell - IND
- Kevin Lorenz - IND